Nucleic Acids Encoding Multimeric Fusion Proteins of TNF Superfamily Ligands
Abstract
A method for constructing stable bioactive fusion proteins of the difficult to express turn or necrosis factor superfamily (TNFSF), and particularly members CD40L (CD 154) and RANKL/TRANCE, with collecting, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these soluble fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be especially useful when these proteins are injected locally as a vaccine adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addition, these and other TNFSF-collectin fusion proteins present new possibilities for the expression of highly active, multimeric, soluble TNFSF members.
Claims
exact text as granted — not AI-modified1 . A method of stimulating a biological response in a subject in need thereof, comprising administering to the subject a composition comprising a multimeric polypeptide of trimer units or a polynucleotide encoding the multimeric polypeptide, each unit comprising:
a collectin family scaffold operably linked to an extracellular domain of a tumor necrosis factor superfamily (TNFSF) polypeptide to form a polypeptide trimer wherein the multimeric polypeptide is at least a dimer of trimer units, thereby stimulating a biological response in the subject.
2 . The method of claim 1 , wherein the subject in need thereof has a tumor.
3 . The method of claim 1 , wherein the subject in need thereof has HIV positive cells.Join the waitlist — get patent alerts
Track US2009263348A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.